Corticosteroid-free adalimumab-cyclophosphamide combination therapy for acute phase neuro-Behçet’s disease: a case report

• Published in: Journal of rheumatic diseases Vol. 31; no. 3; pp. 178 - 181
• Main Authors: Ji Hyoun Kim, Sang Wan Chung, Yun Jong Lee
• Format: Journal Article
• Language: Korean
• Published: 대한류마티스학회 01.07.2024
• Subjects: Adalimumab; Behcet syndrome; Central nervous system; Cyclophosphamide; Vasculitis
• ISSN: 2093-940X

Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Department of Medical Device Development, Seoul National University Graduate School, Seongnam, Korea J Rheum Dis 2024;31(3):178-181 https://doi.org/10.4078/jrd.2023.0069 pISSN: 2093-940X, eISSN: 2233-4718 Case Report Neuro-Behcet's disease (NBD) represents a significant complication of Behcet's syndrome, potentially leading to elevated mortality and disability rates. The standard treatment for parenchymal NBD typically entails administering high-dose corticosteroids to prompt rapid-onset effects, coupled with immunosuppressants to prevent subsequent relapses. A 48-year-old male with NBD presented with progressively worsening dysarthria over 9 months. This patient experienced increased intraocular pressure while using glucocorticoids, which worsened his pre-existing glaucoma. The patient had a prior diagnosis of NBD and presented with progressive dysarthria over a period of nine months, leading to a brain magnetic resonance imaging (MRI) scan. The brain MRI revealed multifocal punctate high signal intensities in the left frontoparietal area, insula, and basal ganglia. Instead of the standard steroid pulse therapy, the patient received adalimumab-cyclophosphamide combination as an alternative induction therapy. Subsequent serial brain MRI scans exhibited no emergence of new lesions, and the patient remained devoid of clinical relapses even after 17 months from the commencement of induction treatment. Adalimumab-cyclophosphamide combination could be used as a corticosteroid-free induction strategy for NBD. Further investigations are warranted to establish the most suitable combination regimen.